Use of Intravenous Tranexamic Acid During Myomectomy

Launched by GEORGE WASHINGTON UNIVERSITY · Dec 2, 2015

Keywords

ClinConnect Summary

Worldwide about 25% of women will develop uterine leiomyomas. Most myomas are asymptomatic however 20 to 25% of women with myomas develop symptoms, such as heavy menstrual bleeding, requiring treatment. For women failing medical management and desiring to preserve fertility and/or their uterus, surgical removal of fibroids (myomectomy) is the major option. Myomectomy is associated with both short and long-term complications, most significantly, hemorrhage and need for conversion to hysterectomy in 2% of cases, need for a blood transfusion in up to 20% of cases, prolonged postoperative stay,...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • women undergoing laparoscopic, robotic or abdominal myomectomy
• • fibroid burden meeting the following criteria based on ultrasound imaging: Fibroids greater than or equal to 10 cm Intramural or Broad Ligament Fibroid greater than or equal to 6 cm Number of fibroids greater than or equal to 5 cm
• Exclusion Criteria:
• • Medical history of the following: thromboembolic disease, ischemic heart disease, malignancy, hematuria, liver disease, chronic kidney disease or subarachnoid hemorrhage
• • pregnant women
• • women who are nursing
• • women with active thrombotic or thromboembolic disease
• • women with history of intrinsic risk of thrombosis or thromboembolism
• • hypersensitivity to Tranexamic Acid
• Concurrent use of:
• • combination of hormonal contraception
• • factor IX complex concentrates
• • Anti-inhibitor coagulant concentrates
• • all-trans retinoic acid